VentriPoint Diagnostics Ltd.
VPTDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 30.34 | -0.87 | -0.83 |
| FCF Yield | -21.56% | -8.03% | -10.27% | -6.54% |
| EV / EBITDA | -3.63 | -9.80 | -7.41 | -10.55 |
| Quality | ||||
| ROIC | 350.53% | -818.83% | -97.97% | -43.74% |
| Gross Margin | 100.00% | 86.28% | 84.80% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.78 | 0.85 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.77% | – | 23.70% | -100.00% |
| Free Cash Flow Growth | 10.98% | 8.05% | -31.28% | -185.39% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | 0.19 | 0.99 | 2.46 |
| Interest Coverage | -26.72 | -84.38 | -174.37 | -286.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 963.33 | -49,180.96 | -27,663.44 | -7,392.33 |